Clinitech laboratory Limited has officially communicated to BSE Limited regarding its exemption from the Annual Secretarial Compliance Report requirement for the financial year ended March 31, 2026. The notification, dated April 15, 2026, was submitted to the Assistant General Manager of the Department of Corporate Services at BSE Limited.

Regulatory Exemption Details

The company's exemption is based on Regulation 15(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. According to this regulation, entities listed on SME exchanges are exempt from several corporate governance provisions that typically apply to mainboard-listed companies.

Scope of Corporate Governance Exemptions

Under the regulatory framework, SME-listed entities are exempted from multiple corporate governance provisions. The exemptions cover regulations 17, 17A, 18, 19, 20, 21, 22, 23, 24, 24A, 25, 26, 27, and specific clauses of regulation 46, along with paragraphs C, D, and E of Schedule V.

The company specifically highlighted that Regulation 24A, which mandates the submission of Annual Secretarial Compliance Reports, does not apply to entities listed on SME exchanges. This exemption allows SME-listed companies to operate with reduced compliance burdens while maintaining essential regulatory oversight.

Management Authorization

The undertaking was formally signed by Jagdish Umakant Nayak, Chairman and Managing Director of Clinitech Laboratory Limited. The digital signature was applied on April 15, 2026, at 13:05:55 +05'30', providing official authorization for the regulatory communication.

The communication serves as an official record with BSE Limited, ensuring transparency regarding the company's compliance status and regulatory obligations as an SME-listed entity.

Clinitech laboratory Limited has announced a significant operational change regarding its market maker arrangement. The Board of Directors approved the transition from SVCM Securities Private Limited to Kalpalabdhi Financials Private Limited as the company's new market maker, effective April 10, 2026.

Board Resolution and Timeline

The Board of Directors passed the resolution for this change through circulation on April 09, 2026. The appointment of the new market maker becomes effective from April 10, 2026. This swift transition ensures minimal disruption to market making activities for the company's shares.

Reason for Market Maker Change

The change in market maker became necessary due to the discontinuation of services by SVCM Securities Private Limited. The existing market maker ceased its market making operations due to internal restructuring within the organization, with effect from April 09, 2026. This internal restructuring at SVCM Securities prompted Clinitech Laboratory to secure alternative market making arrangements.

Tripartite Agreement Details

A comprehensive tripartite agreement has been executed between three parties to formalize the new arrangement:

The agreement was executed on April 09, 2026, establishing the framework for the new market making arrangement.

Regulatory Compliance

Clinitech Laboratory Limited has committed to fulfilling all regulatory requirements associated with this change. The company will submit necessary applications to SEBI and the stock exchange within the prescribed time limit to update and intimate the change in market maker. This disclosure has been made pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, ensuring transparency and compliance with regulatory obligations.

Market Making Agreement Structure

The nature of the agreement is classified as a Market Making Agreement, designed to ensure adequate liquidity and price discovery for Clinitech Laboratory's shares. The new arrangement with Kalpalabdhi Financials Private Limited is expected to maintain continuity in market making services following the transition from the previous provider.